Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.

Phase 3

Completed

• Conditions: Pain

• Registration Number: NCT00141362
• Lead Sponsor: Pfizer

Brief Summary

Evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-10
• Study Completion: 2005-08
• Study First Submitted: 2005-08-30
• Study First Submitted QC: 2005-08-31
• Study First Posted: 2005-09-01
• Status Verified: 2006-12
• Last Update Submitted: 2006-12-29
• Last Update Posted: 2007-01-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 325

Inclusion Criteria

• Must have met the inclusion criteria for the preceding double-blind BID study in diabetic neuropathy or postherpetic neuralgia.
• Must have received study medication under double-blind conditions.

Exclusion Criteria

• Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety and efficacy